메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류
인문학
인문학 일반 역사학 철학 종교학 어문학 기타 인문학
사회과학
사회과학 일반 경영학 관광학 교육학 군사학 문헌정보학 법학 사회학 신문방송학 심리과학 정치외교학 지리학 행정학 경제학 무역학 인류학 기타 사회과학
자연과학
자연과학 일반 물리학 생물학 생활과학 수학·통계학 천문학 지구과학 화학 기타 자연과학
공학
공학 일반 건축공학 기계공학 산업공학 재료·에너지공학 전기전자공학 조선해양공학 화학공학 컴퓨터학 기타공학
의약학
의학 일반 간호학 수의학 약학 한의학 기초의학 임상의학 기타 의약학
농수해양학
농수해양학 일반 농학 수산학 식품과학 임학 축산학 해상운송학 기타 농수해양학
예술체육학
예술 일반 디자인 미술 미용 사진 음악학 의상 체육 공연매체예술 기타 예술체육학
복합학
학제간연구 과학기술학 뇌인지과학 기술정책 기타 복합학

ENG

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한암학회 Cancer Research and Treatment Cancer Research and Treatment 제37권 제6호
발행연도
2005.1
수록면
332 - 338 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: We prospectively conducted a multi-center,open-label, randomized phase II trial to compare the efficacy and safety of docetaxel plus cisplatin (DC) and etoposideplus cisplatin (EC) for treating advanced stage non-small cell lung cancer (NSCLC). Materials and Methods: Seventy-eight previously untreated patients with locally advanced, recurrent or metastatic NSCLC were enrolled in this study. The patientsreceived cisplatin 75 mg/m2 on day 1 and either docetaxel 75 mg/m2 on day 1 or etoposide 100 mg/m2 on days 1 to 3 in the DC or EC arm, respectively, every 3 weeks. Results: The objective response rate was 39.4% (15/38) and 18.4% (7/38) (p=0.023) in the DC and EC arms, respectively. The median time to progression (TTP) was5.9 and 2.7 months (p=0.119), and the overall survival was 12.1 and 8.7 months (p=0.168) in the DC and EC arms, respectively. The prognostic factors for longer survival were an earlier disease stage (stage III, p=0.0095), the responders to DC (p=0.0174) and the adenocarcinoma histology (p=0.0454). The grades 3 and 4 toxicities were similar in both arms, with more febrile neutropenia (7.9% vs. 0%) and fatigue (7.9% vs. 0%) being noted in the DC arm. Conclusion: DC offered a superior overall response rate than does EC, along with tolerable toxicity profiles, although the DC drug combination did not show significantlyimproved survival and TTP.
#Docetaxel #Etoposide #Cisplatin #Non-small cell lung carcinoma

목차

등록된 정보가 없습니다.

참고문헌 (1)

참고문헌 신청
/ 1991 / Chemotherapy for nonsmallcell lung cancer : 1326 ~ 8 | 2. [학술지(정기간행물)] - / 2001 / Cancer: principlesand practice of oncology. 6th ed. : 925 ~ 83 | 3. [학술지(정기간행물)] - / 1998 / New chemotherapeutic agents prolongsurvival and improve quality of life in non-small cell lung cancer:a review of the literature and future directions 4 : 1087 ~ 100 | 4. [학술지(정기간행물)] - / 1994 / Chemotherapy vs supportive care in advanced non-small-celllung cancer Results of a meta-analysis of the literature : 861 ~ 5 | 5. [학술지(정기간행물)] - / 1995 / Chemotherapyin non-small cell lung cancer: a meta-analysis usingupdated data on individual patients from 52 randomizedclinical trials 311 : 899 ~ 909 | 6. [학술지(정기간행물)] - / 19931866-72 / Chemotherapy for advancednon-small-cell lung cancer | 7. [학술지(정기간행물)] - / 1999 / Mitomycin, ifosfamide, andcisplatin in unresectable non-small-cell lung cancer: effects onsurvival and quality of life. 17 : 3188 ~ 94 | 8. [학술지(정기간행물)] - / 1992 / Chemotherapy of lung cancer 327 : 1434 ~ 41 | 9. [학술지(정기간행물)] - / 1994 / The treatment of non-small cell lung cancer : 6 49 ~ 59 | 10. [학술지(정기간행물)] - / 2000 / Prospective randomized trial of docetaxelversus best supportive care in patients with non-small-cell lungcancer previously treated with platinum-based chemotherapy 18 : 2095 ~ 103 | 11. [학술지(정기간행물)] - / 2002 / Second line chemotherapyfor NSCLC: establishing a gold standard 38 : 5 ~ 12 | 12. [학술지(정기간행물)] - / 2004 / American Society of Clinical Oncology treatmentof unresectable non-small-cell lung cancer guideline:update 2003 22 : 330 ~ 53 | 13. [학술지(정기간행물)] - / 1998 / Phase II study of docetaxel and cisplatin inadvanced non-small-cell lung cancer 16 : 1948 ~ 53 | 14. [학술지(정기간행물)] - / 1998 / First-line treatment ofadvanced non-small-cell lung cancer with docetaxel and cisplatin:a multicenter phase II study 9 : 331 ~ 4 | 15. [학술지(정기간행물)] - / 2003 / phase III studyof docetaxel plus platinum combinations versus vinorelbineplus cisplatin for advanced non-small-cell lung cancer: theTAX 326 Study Group. 21 ( ) : 3016 ~ 24 | 16. [학술지(정기간행물)] - / 1986 / Therapy with cisplatin and etoposide for nonsmall-cell lung cancer : 3 104 ~ 14 | 17. [학술지(정기간행물)] - / 1989 / The expanding role of cisplatin in the treatmentof non-small-cell lung cancer : 6 10 ~ 21 | 18. [학술지(정기간행물)] - / 1991 / Phase II trial of sequential VP-16 cisplatin combinationchemotherapy and radiotherapy for locally advanced : 131 ~ 9 | 19. [학술지(정기간행물)] - / 1999 / Prolonged oral etoposide in combination with intravenouscisplatin for advanced non-small cell lung cancer 31 : 105 ~ 11 | 20. [학술지(정기간행물)] - / 2000 / Concurrent chemoradiation therapy with cisplatin andoral etoposide for locally advanced non-small cell lung cancer 32 : 682 ~ 9 | 21. [학술지(정기간행물)] - / 2002 / Consensus on medical treatment ofnon-small cell lung cancer 38 : 63 ~ 13 | 22. [학술지(정기간행물)] - / 2004 / Phase III randomized trial of docetaxel pluscisplatin versus vindesine plus cisplatin in patients with stageIV non-small-cell lung cancer:the Japanese Taxotere LungCancer Study Group 22 : 254 ~ 61 | 23. [학술지(정기간행물)] - / 2001 / Randomized phase III trial of paclitaxelplus carboplatin versus vinorelbine plus cisplatin in the treatmentof patients with advanced non--small-cell lung cancer:a Southwest Oncology Group trial 19 : 3210 ~ 8 | 24. [학술지(정기간행물)] - / 2005 / Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastaticnon-small cell lung cancer 16 : 1069 ~ 75 | 25. [학술지(정기간행물)] - / 2002 / Comparison of four chemotherapy regimens foradvanced non-small-cell lung cancer 346 : 92 ~ 8 google schola

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0